Atamestane: An aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review
- 1 March 1993
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 44 (4-6) , 565-572
- https://doi.org/10.1016/0960-0760(93)90260-4
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- The prostate: An increasing medical problemThe Prostate, 1990
- Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic interventionThe Prostate, 1990
- Etiology and disease process of benign prostatic hyperplasiaThe Prostate, 1989
- Aromatase-inhibitors of the androstenedione-type activate the 17β-hydroxysteroid-dehydrogenase in the rat testis tissue suspension modelJournal of Steroid Biochemistry, 1988
- Aromatase inhibitors: Their biochemistry and clinical potentialJournal of Steroid Biochemistry, 1987
- Potential clinical role of new aromatase inhibitorsSteroids, 1987
- Estrogens and benign prostatic hyperplasia: The basis for aromatase inhibitor therapySteroids, 1987
- Aromatase inhibitors and benign prostatic hyperplasiaJournal of Steroid Biochemistry, 1986
- 1-methyl-1,4-androstadiene-3,17-dione (SH 489): Characterization of an irreversible inhibitor of estrogen biosynthesisJournal of Steroid Biochemistry, 1986
- Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: Preliminary resultsThe Prostate, 1986